Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
January 14, 2025 16:05 ET
|
Vericel Corporation
Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest...
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
January 08, 2025 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the...
Vericel Reports Third Quarter 2024 Financial Results
November 07, 2024 07:55 ET
|
Vericel Corporation
Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third...
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
October 24, 2024 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
August 29, 2024 09:17 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
August 26, 2024 07:45 ET
|
Vericel Corporation
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI’s $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 ...
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
August 15, 2024 16:05 ET
|
Vericel Corporation
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in...
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
August 07, 2024 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Reports Second Quarter 2024 Financial Results
August 01, 2024 07:55 ET
|
Vericel Corporation
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% ...
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
July 22, 2024 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the...